drugset / Trial / NCT00351923

Immunogenicity/Safety of Measles-Mumps-Rubella-Varicella Vaccine (MeMuRu-OKA): Using Two Different Administration Routes

NCT00351923

Phase 3 Completed 330 enrolled GlaxoSmithKline
RandomizedParallel-groupOpen-labelPrevention

Summary

This study will compare the immunogenicity and safety of the MeMuRu-OKA vaccine administered subcutaneously or using an alternative administration route.

Timeline

Start
2006-03
Primary completion
Completion
2006-12

Drugs

EvaluationDrugModalityDoseRoute
Subject MeMuRu-OKA Vaccine Subcutaneous